Independent reference. Not affiliated with, endorsed by, or speaking for the U.S. Food and Drug Administration.
FDA Medication Tracker

← All approvals · Cancer · 2026

Rasonque (daraxonrasib)

The FDA approved Rasonque (daraxonrasib) on August 26, 2026 to treat metastatic pancreatic cancer.
Brand name
Rasonque
Generic name
daraxonrasib
FDA approval date
August 26, 2026
Approved use (FDA wording)
To treat metastatic pancreatic cancer
Company
Revolution Medicines
Application
NDA220910
Dosage form / route
TABLET · ORAL
Boxed warning on label
Not listed
Category on this site
Cancer

Indications and usage, from the FDA label

RASONQUE is indicated for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy. RASONQUE is an inhibitor of the RAS GTPase family, indicated for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy. ( 1 )

Official sources

Facts only. This site lists what the FDA has approved and what the FDA says each drug is approved for, quoted or closely paraphrased from FDA and openFDA records. It gives no medical advice, no dosing, and no comparisons, and it says nothing about whether a drug is right for anyone. Talk to a licensed clinician about any medication. Records can lag or contain errors; the FDA's own pages are authoritative.